DOCSLIB.ORG

Luteinizing Hormone-Releasing Hormone Antagonists

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Luteinizing Hormone-Releasing Hormone Antagonists d Lt n 1. Introduction io 2. LH-RHK antagonistst versus U u , a ib ad tr lo 3.m LH-RHagonists antagonists n r is ow . fo D d se Luteinizing hormone-releasing 4. LH-RH antagonists an for l u In l c a a rs on 9 i e rs hormone antagonists 0 fertilizationrc us e 0 5. LH-RH antagonistsd r p in tumor e e fo 2 m ris y Ga ´ © ho op † bor Mezo 6.m Cetrorelixtherapyt (CET) c E€ t Au e otv h o . gl 1117 Budapest,os€ Lora Pa 7.C Abarelixd in ig ite s in vitro † r r ib a ´ o8. Ganirelixh t Background: nd University,& Marilena Hungarian Manea Academy of Sciences, Research Group of Peptide Chemistry, y ro rin p le p p role in the vertebrate reproduction by regulating gonadal activity. Based on o a 9.se LH-RHnd antagonists: new C S u a its binding to pituitary´zma LH-RH receptors, as well as to LH-RH receptors ed w ´ r is ie ny P. stny. 1/A, Hungary o or , vcandidates for clinical expressed on cancerLuteinizing cells, LH-RH hormone-releasing agonists and antagonists hormone have (LH-RH) been plays devel- a central f th ay t u 10.pl Orallyapplications active non-peptidic oped for different therapeutic applications. o na is N U d an overview of the most relevant LH-RH antagonists and their therapeutic Review applications. Recently patented compounds as well as drug formulations and 11. Expertantagonists opinion of LH-RH receptors dosage are presented. applications in osis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists. in vitro Keywords: Conclusion: luteinizing hormone-releasing hormone, LH-RHfertilization, antagonists, non-peptidic benign prostatic LH-RH hyperplasia, antagonists, endometri- tumor therapy gonadotropin-releasing hormone, hormone-dependent tumors, Objective/method: LH-RH antagonists have found clinical Expert Opin. Ther. Patents (2009) 1. Introduction Here we give The hypothalamic decapeptide luteinizing hormone-releasing hormone (LH-RH; Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH ing hormone (GnRH), was discovered in 1971 by Andrew V. Schally and his colleagues 19 structure and synthesis.) The primary biological function(12):1771-1785 of LH-RH is the regulation of the gonadal activity by releasing gonadotropic hormones, luteinizing hormone [1] (LH) and follicle stimulating. (Schally’s hormone group was (FSH), the first from to the accomplish anteriorpituitary its isolation, gland, elucidation that of act on the female and male gonads to trigger the gametogenesis, as well as the synthesis in vitro and release of sex-steroids. Therefore, this neurohormone plays a central role in vertebrate reproduction fertilization, thalamic neurons exposure to LH-RH results in the suppression of gonadotropin and sex-steroid secretion due to the desensitization of gonadotropic cells and the downregulation of pituitary LH-RH receptors (LH-RH-Rs) 2 ), also called gonadotropin-releas- medical approach to therapy[3] of hormone-dependent tumors such as prostate and [2] breast tumors, benign prostatic hyperplasia,and it has. LH-RH a endometriosisshort half-life is secreted and in female a pulsatile infertility fashion by the hypo- Since the discovery of LH-RH, 23 natural isoforms have been identified thousand synthetic agonists and antagonists have been developed and some of them have found therapeutic applications (e.g., buserelin, goserelin, triptorelin and leuprolide as superagonists; cetrorelix, abarelix and ganirelix as antagonists) in vivo 2. LH-RH antagonists versus agonists [5] of 2 – 5 min By modifying the Gly . The observed chemical castration is a derivatives can be produced. Gly [4] . Continuous 6 and Gly 10 6 in mammalian LH-RH (LH-RH-I), superagonist is replaced by D-amino acid derivatives with bulky [7] , several[6] . [8] . 1771 Luteinizing hormone-releasing hormone antagonists A. LH-RH agonist B. LH-RH antagonist IVF Endometriosis and BPH Cancer Castration level Serum hormone level Serum hormone level 10 20 Days 4 8 12 24 Hours Figure 1. Effect of LH-RH agonists (A) and antagonists (B) on serum hormone levels (e.g., LH, FSH, testosterone, estradiol levels). BPH: Benign prostatic hyperplasia; IVF: In vitro fertilization; LH-RH: Luteinizing hormone-releasing hormone. apolaric side chain (Leu, Trp, Ser(tBu), His(Bzl)), while Pro9- variety of amino acid derivatives have been substituted 10 Gly -NH2 is modified as Pro-NHEt or Pro-Azgly-NH2 [9]. (Figure 2). At present, cetrorelix (Æterna Zentaris), abarelix Compared to the natural LH-RH, five or more substitutions (Preacis) and ganirelix (Organon, Inc.) are on the market, of the amino acids in positions 1 – 3, 6, 10, (5, 8) are required while antarelix/teverelix (Ardana), degarelix (Ferring Pharma- for the preparation of antagonists [10]. ceutical), ozarelix (Æterna Zentaris), ornirelix (Oakwood Lab- The main difference between LH-RH antagonists and oratories), iturelix (Ares Serono), azaline B and acyline agonists is represented by their mode of action on the release (NICHD/Salk Institute) are in clinical trials (Table 1) [15-26]. of gonadotropins. After an initial stimulatory effect, the The main areas where LH-RH antagonists are or could be agonists lead to the desensitization of gonadotropic cells recommended are the in vitro fertilization (IVF), benign and to a decrease in the number of LH-RH-R on the cell prostatic hyperplasia (BPH), endometriosis and cancer ther- membrane (downregulation), followed by the reduction of LH apy [10,26-28]. The administration of LH-RH antagonists leads and FSH release [10,11]. The blockade of the production of to a reduction of serum hormone levels in a dose-dependent gonadotropins results in the inhibition of sex-steroid produc- manner. Since the hormone level required for various ther- tion. The complete inhibition can be reached in 15 – 20 days, apeutic applications is different (Figure 1B), the dose of LH- causing a subsequent delay in the therapeutic benefit RH antagonists must be carefully chosen. In the case of IVF, (Figure 1A) [12]. The temporary increase of sex-steroids (e.g., the complete hormonal withdrawal should be avoided, while testosterone surge) can exacerbate the hormone-sensitive can- chemical castration is needed for efficient tumor therapy. The cers and may cause catastrophic flare events such as spinal-cord attainment of a low, but not completely reduced hormone compression and urinary-tract obstruction. This clinical flare level in BPH and endometriosis is also recommended [12]. should be avoided especially in the case of cancer metasta- Some of the LH-RH antagonists such as cetrorelix and sis [13]. The application of LH-RH antagonists results in an ganirelix are efficient in IVF and employed for assisted immediate decrease of LH and FSH levels by a rapid, but reproduction technology (ART) treatment [11]. However, reversible blockade of LH-RH-Rs without any flare abarelix is not suitable for this application, but it is effective (Figure 1B). However, many of the first and second generation in tumor therapy [29]. At present, abarelix is the only LH-RH antagonists showed anaphylactic reactions due to the hista- antagonist clinically used as an antineoplastic agent. The mine release, which prevented their application in clinical studies with cetrorelix indicate that the dosage of the LH- trials [10,14]. This side effect was greatly reduced in the third RH antagonist might influence the therapeutic application [12]. generation LH-RH antagonists (e.g., cetrorelix, ganirelix). A low dose for IVF (clinical application) [11,12], a medium dose Some of these antagonists are currently on the market and for BPH (Phase III clinical trial) [12,29] and a high dose for the others are in clinical trials. prostate cancer treatment (Phase I clinical trial) are neces- sary [12]. However, the high dose might cause unwanted side 3. LH-RH antagonists effects due to the fact that cetrorelix has higher histamine- releasing properties than other LH-RH antagonists such as The most promising third and fourth generation LH-RH abarelix, ganirelix and degarelix [30]. Therefore, in addition to antagonists contain Ac-D-Nal-D-Cpa-D-Pal in the N-terminal new compounds (e.g., degarelix [31], ozarelix [32], non-peptidic part and D-Ala in position 10. In positions 5, 6 and 8, a large antagonists [33]), most of the recent patents are focused on the 1772 Mezo & Manea Cl O OH O O R1 O R3 O R5 H H HN N N N O N N N N H H H H O R O O R2 O 4 N N NH H 2 N O R1 = H (Tyr), CH3 (N-Me-Tyr) O N OH HN NH H R2 = N HN O O O Tyr Aph(Hor) Lys(Pic) N HN N H N H NH N 2 N HN O O O Lys(Nic) Aph(Ac) Aph(Atz) Figure 2. Chemical structures of LH-RH antagonists. 6Anic: 6-Aminonicotinoyl; Aph: 4-Aminophenylalanine; Atz: 5¢-(3¢-Amino-1H-1¢,2¢,4¢-triazolyl); Cit: Citruline; Cba: Carbamoyl; Cpa: 4-Chlorophenylalanine; Et: Ethyl; hArg: Homoarginine; hCit: Homocitruline; Hor: L-Hydroorotyl; iPr: Isopropyl; LH-RH: Luteinizing hormone-releasing hormone; Nal: 2-Naphtylalanine; Nic: Nicotinoyl; Nle: Norleucine; Pal: 3-Pyridylalanine; Pic: Picoloyl. development of drug formulations [34,35], dosage [36] and a patients [39,40]. Both LH-RH agonists and antagonists are more convenient route of administration [37,38]. used in ovarian stimulation for IVF. Due to their different mechanisms of action, the antagonists have several advantages 4. LH-RH antagonists for in vitro fertilization in comparison with the agonists [10,41]. In contrast to LH-RH agonists, the increase of the premature LH can be prevented The in vitro fertilization process involves controlled ovarian easier and faster by antagonists (within a few hours instead of stimulation (COS) to stimulate the follicular growth.
Load more

Recommended publications
  • Hormones and Breeding
    IN-DEPTH: REPRODUCTIVE ENDOCRINOLOGY Hormones and Breeding Carlos R.F. Pinto, MedVet, PhD, Diplomate ACT Author’s address: Theriogenology and Reproductive Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210; e-mail: [email protected]. © 2013 AAEP. 1. Introduction affected by PGF treatment to induce estrus. In The administration of hormones to mares during other words, once luteolysis takes place, whether breeding management is an essential tool for equine induced by PGF treatment or occurring naturally, practitioners. Proper and timely administration of the events that follow (estrus behavior, ovulation specific hormones to broodmares may be targeted to and fertility) are essentially similar or minimally prevent reproductive disorders, to serve as an aid to affected (eg, decreased signs of behavioral estrus). treating reproductive disorders or hormonal imbal- Duration of diestrus and interovulatory intervals ances, and to optimize reproductive efficiency, for are shortened after PGF administration.1 The example, through induction of estrus or ovulation. equine corpus luteum (CL) is responsive to PGF These hormones, when administered exogenously, luteolytic effects any day after ovulation; however, act to control the duration and onset of the different only CL Ͼ5 days are responsive to one bolus injec- stages of the estrous cycle, specifically by affecting tion of PGF.2,3 Luteolysis or antiluteogenesis can duration of luteal function, hastening ovulation es- be reliably achieved in CL Ͻ5 days only if multiple pecially for timed artificial insemination and stimu- PGF treatments are administered. For that rea- lating myometrial activity in mares susceptible to or son, it became a widespread practice to administer showing delayed uterine clearance.
    [Show full text]
  • Kisspeptin and Testicular Function—Is It Necessary?
    International Journal of Molecular Sciences Review Kisspeptin and Testicular Function—Is It Necessary? Aditi Sharma 1 , Thilipan Thaventhiran 1, Suks Minhas 2, Waljit S. Dhillo 1 and Channa N. Jayasena 1,* 1 Section of Investigative Medicine, Imperial College, 6th Floor, Commonwealth Building, Hammersmith Hospital, 150 Du Cane Road, London W12 0NN, UK; [email protected] (A.S.); [email protected] (T.T.); [email protected] (W.S.D.) 2 Department of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, Hammersmith, London W6 8RF, UK; [email protected] * Correspondence: [email protected] Received: 12 March 2020; Accepted: 21 April 2020; Published: 22 April 2020 Abstract: The role of kisspeptin in stimulating hypothalamic GnRH is undisputed. However, the role of kisspeptin signaling in testicular function is less clear. The testes are essential for male reproduction through their functions of spermatogenesis and steroidogenesis. Our review focused on the current literature investigating the distribution, regulation and effects of kisspeptin and its receptor (KISS1/KISS1R) within the testes of species studied to date. There is substantial evidence of localised KISS1/KISS1R expression and peptide distribution in the testes. However, variability is observed in the testicular cell types expressing KISS1/KISS1R. Evidence is presented for modulation of steroidogenesis and sperm function by kisspeptin signaling. However, the physiological importance of such effects, and whether these are paracrine or endocrine manifestations, remain unclear. Keywords: kisspeptin; kisspeptin receptor; spermatozoa; Leydig cells; Sertoli cells; testes; testosterone; LH; FSH; spermatogenesis 1. Introduction Kisspeptin is an established regulator of puberty onset [1,2], sexual maturation and adult reproductive activity [3].
    [Show full text]
  • LHRH) Antagonist Cetrorelix and LHRH Agonist Triptorelin on the Gene Expression of Pituitary LHRH Receptors in Rats
    Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats Magdolna Kovacs*†‡ and Andrew V. Schally*†§ *Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA 70112; and †Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112 Contributed by Andrew V. Schally, August 21, 2001 The mechanisms through which luteinizing hormone (LH)-releasing however, are different. LHRH agonists achieve the inhibition of hormone (LHRH) antagonists suppress pituitary gonadotroph func- gonadotropin secretion after a period of continuous exposure (1, tions and LHRH-receptor (LHRH-R) expression are incompletely un- 2, 11–14). In contrast, antagonists of LHRH produce a compet- derstood. Consequently, we investigated the direct effect of LHRH itive blockade of LHRH-R and cause an immediate cessation of antagonist cetrorelix in vitro on the expression of the pituitary the release of gonadotropins and sex steroids, reducing the time LHRH-R gene and its ability to counteract the exogenous LHRH and of the onset of therapeutic effects as compared with the agonists the agonist triptorelin in the regulation of this gene. We also com- (1, 2, 15–17). LHRH agonists such as triptorelin, leuprolide, pared the effects of chronic administration of cetrorelix and triptore- buserelin, or goserelin (1, 2, 14) have been used worldwide for lin on the LHRH-R mRNA level and gonadotropin secretion in ovari- nearly two decades, but LHRH antagonists such as cetrorelix, ectomized (OVX) and normal female rats. The exposure of pituitary ganirelix, and Abarelix have been introduced into the clinical cells in vitro to 3-min pulses of 1 nM LHRH or 0.1 nM triptorelin for 5 h practice relatively recently (1, 2, 15, 16).
    [Show full text]
  • Personalized ADT
    Personalized ADT Thomas Keane MD Conflicts • Ferring • Tolemar • Bayer • Astellas • myriad Personalized ADT for the Specific Paent • Cardiac • OBesity and testosterone • Fsh • High volume metastac disease • Docetaxol • Significant LUTS Cardiovascular risk profile and ADT Is there a difference? Degarelix Belongs to a class of synthe@c drug, GnRH antagonist (Blocker) GnRH pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly NH2 Leuprolide D-Leu NEt Goserelin D-Ser NH2 LHRH agonists Triptorelin D-Trp NH2 Buserelin D-Ser NEt Degarelix D-NaI D-Cpa D-PaI Aph D-Aph D-Ala NH2 N-Me ABarelix D-NaI D-Cpa D-PaI D-Asn Lys D-Ala NH2 Tyr GnRH antagonists Cetrorelix D-NaI D-Cpa D-PaI D-Cit D-Ala NH2 Ganirelix D-NaI D-CPa D-PaI D-hArg D-hArg D-Ala NH2 Millar RP, et al. Endocr Rev 2004;25:235–75 Most acute CVD events are caused By rupture of a vulnerable atherosclero@c plaque The vulnerable plaque – thin cap with inflammaon Inflammation Plaque instability is at the heart of cardiovascular disease Stable plaque Vulnerable plaque Lumen Lumen Lipid core Lipid core FiBrous cap FiBrous cap Thick Cap Thin Rich in SMC and matrix Composion Rich in inflammatory cells: proteoly@c ac@vity Poor Lipid Rich Inflammatory Inflammatory state Highly inflammatory LiBBy P. Circulaon 1995;91:2844-2850 Incidence of Both prostate cancer and CV events is highest in older men Prostate cancer CV events 3500 3500 Prostate cancer All CV disease Major CV events 3000 3000 2827.1 2500 2500 2338.9 2000 2000 1719.7 1500 1500 1152.6 1008.7 1038.7 1000 1000 641.2 545.2 571.1 Age-specific incidence per 100,000 person-years 500 500 246.9 133.7 4.3 0 0 40-49 50-59 60-69 70-79 80-89 90-99 40-49 50-59 60-69 70-79 80-89 90-99 CV, cardiovascular Major CV events = myocardial infarc@on, stroke, or death due to CV disease All CV disease = major CV events + self-reported angina or revascularisaon procedures Driver, et al.
    [Show full text]
  • Hertfordshire Medicines Management Committee (Hmmc) Nafarelin for Endometriosis Amber Initiation – Recommended for Restricted Use
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) NAFARELIN FOR ENDOMETRIOSIS AMBER INITIATION – RECOMMENDED FOR RESTRICTED USE Name: What it is Indication Date Decision NICE / SMC generic decision status Guidance (trade) last revised Nafarelin A potent agonistic The hormonal December Final NICE NG73 2mg/ml analogue of management of 2020 Nasal Spray gonadotrophin endometriosis, (Synarel®) releasing hormone including pain relief and (GnRH) reduction of endometriotic lesions HMMC recommendation: Amber initiation across Hertfordshire (i.e. suitable for primary care prescribing after specialist initiation) as an option in endometriosis Background Information: Gonadorelin analogues (or gonadotrophin-releasing hormone agonists [GnRHas]) include buserelin, goserelin, leuprorelin, nafarelin and triptorelin. The current HMMC decision recommends triptorelin as Decapeptyl SR® injection as the gonadorelin analogue of choice within licensed indications (which include endometriosis) link to decision. A request was made by ENHT to use nafarelin nasal spray as an alternative to triptorelin intramuscular injection during the COVID-19 pandemic. The hospital would provide initial 1 month supply, then GPs would continue for further 5 months as an alternative to the patient attending for further clinic appointments for administration of triptorelin. Previously at ENHT, triptorelin was the only gonadorelin analogue on formulary for gynaecological indications. At WHHT buserelin nasal spray 150mcg/dose is RED (hospital only) for infertility & endometriosis indications. Nafarelin nasal spray 2mg/ml is licensed for: . The hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist. Use of nafarelin in endometriosis aims to induce chronic pituitary desensitisation, which gives a menopause-like state maintained over many months.
    [Show full text]
  • Ganirelix) May Prevent Ovarian Hyperstimulation Syndrome Caused by Ovarian Stimulation for In-Vitro Fertilization
    Human Reproduction vol.13 no.3 pp.573–575, 1998 CASE REPORT High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization D.de Jong1, N.S.Macklon1, B.M.J.L.Mannaerts2, releasing hormone (GnRH) agonists in order to prevent H.J.T.Coelingh Bennink2 and B.C.J.M.Fauser1,3 unpredictable changes in release of endogenous gonadotrophins. However, it has been reported that the continued administration 1Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Dijkzigt Academic Hospital and Erasmus University of GnRH agonists does not affect subsequent ovarian quiescence Medical School, Dr. Molewaterplein 40, 3015 GD, Rotterdam and (Wadaet al., 1992). This may be related to prolonged suppression 2Scientific Development Group, NV Organon, Oss, The Netherlands of pituitary function due to slow recovery from down-regulation 3To whom correspondence should be addressed (Donderwinkel et al., 1993). Some residual gonadotrophin release may remain during GnRH agonist suppression, whereas This case report describes the first attempt to treat pituitary release of LH and follicle-stimulating hormone (FSH) imminent ovarian hyperstimulation syndrome (OHSS) by may be virtually abolished with the sustained use of a high dose using a gonadotrophin-releasing hormone (GnRH) of GnRH antagonist. In this case report we describe an alternative antagonist. A 33 year old, normo-ovulatory woman under- method, using a high dose of a GnRH antagonist which may going in-vitro fertilization received daily subcutaneous decrease the risk of a severe OHSS. injections of 150 IU of recombinant follicle-stimulating hormone (recFSH) from cycle day 2, together with GnRH antagonist (ganirelix) 0.125 mg from cycle day 7 onwards.
    [Show full text]
  • Human Chorionic Gonadotropin (HCG), a Polypeptide Hormone Produced by the Human
    45792G/Revised: April 2011 CHORIONIC GONADOTROPIN FOR INJECTION, USP DESCRIPTION: Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human placenta, is composed of an alpha and a beta sub-unit. The alpha sub-unit is essentially identical to the alpha sub-units of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha sub-unit of human thyroid-stimulating hormone (TSH). The beta sub-units of these hormones differ in amino acid sequence. Chorionic gonadotropin is obtained from the human pregnancy urine. It is standardized by a biological assay procedure. Chorionic Gonadotropin for Injection, USP is available in multiple dose vials containing 10,000 USP Units with accompanying Bacteriostatic Water for Injection for reconstitution. When reconstituted with 10 mL of the accompanying diluent each vial contains: Chorionic gonadotropin 10,000 Units Mannitol 100 mg Benzyl alcohol 0.9% Water for Injection q.s. Buffered with dibasic sodium phosphate and monobasic sodium phosphate. Hydrochloric acid and/or sodium hydroxide may have been used for pH adjustment (6.0­ Reference ID: 2933198 8.0). Nitrogen gas is used in the freeze drying process. CLINICAL PHARMACOLOGY: The action of HCG is virtually identical to that of pituitary LH, although HCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone. Androgen stimulation in the male leads to the development of secondary sex characteristics and may stimulate testicular descent when no anatomical impediment to descent is present.
    [Show full text]
  • Gonadotropin and Testosterone Measurements After
    Pediat. Res. 10: 46-51 (1976) Estradiol puberty estrogen sexual differentiation gonadotropins testosterone maturation Gonadotropin and Testosterone Measurements after Estrogen Administration to Adult Men, Prepubertal and Pubertal Boys, and Men with Hypogonadotropism: Evidence for Maturation of Positive Feedback in the Male HOWARD E. KULIN"" AND EDWARD 0. REITER Reproduction Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA Extract MATERIALS AND METHODS Nineteen male subjects were given five daily injections of SUBJECTS 17~-estradiol and circulating levels of estradiol (E 2 ), testosterone (T), and gonadotropins were determined by radioimmunoassay Seven normal, adult men (ages 20-22) and one male (age 21) before, during, and after the steroid course. Peak levels of E 2 with the syndrome of vanishing testes (I) were hospitalized for attained during the 5 days of treatment ranged from 173-577 pg/ml. study at the Clinical Center of the National Institutes of Health. Four of seven normal adult men and one castrate man demonstrated Each patient was given five daily intramuscular injections of IO or suppression of follicle-stimulating hormone ( FSH) and luteinizing 15 ,ug/kg body weight of 17~-estradiol (E2 ) (20) and blood samples hormone ( LH) with a subsequent rise in LH ( positive feedback) were obtained every 12-24 hr before, during, and after the estrogen while E 2 levels remained elevated. A rise in T was associated with course (see Table I). the LH increment in the four normal men. Nine pre-, early, or Nine endocrinologically normal boys between the ages of 7 and midpubertal boys and two men with hypogonadotropic hypogo­ 18 were studied in the course of evaluation for short stature, nadism displayed only gonadotropin suppression after E 2 adminis­ precocious puberty, or delayed adolescence.
    [Show full text]
  • Degarelix for Treating Advanced Hormone- Dependent Prostate Cancer
    CONFIDENTIAL UNTIL PUBLISHED NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Degarelix for treating advanced hormone- dependent prostate cancer This guidance was developed using the single technology appraisal (STA) process 1 Guidance 1.1 Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. 1.2 People currently receiving treatment initiated within the NHS with degarelix that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop. 2 The technology 2.1 Degarelix (Firmagon, Ferring Pharmaceuticals) is a selective gonadotrophin-releasing hormone antagonist that reduces the release of gonadotrophins by the pituitary, which in turn reduces the secretion of testosterone by the testes. Gonadotrophin- releasing hormone is also known as luteinising hormone-releasing hormone (LHRH). Because gonadotrophin-releasing hormone antagonists do not produce a rise in hormone levels at the start of treatment, there is no initial testosterone surge or tumour stimulation, and therefore no potential for symptomatic flares. National Institute for Health and Care Excellence Page 1 of 71 Final appraisal determination – Degarelix for treating advanced hormone-dependent prostate cancer Issue date: April 2014 CONFIDENTIAL UNTIL PUBLISHED Degarelix has a UK marketing authorisation for the ‘treatment of adult male patients with advanced hormone-dependent prostate cancer’. It is administered as a subcutaneous injection. 2.2 The most common adverse reactions with degarelix are related to the effects of testosterone suppression, including hot flushes and weight increase, or injection site reactions (such as pain and erythema).
    [Show full text]
  • Fertility Medications: Bravelle®, Cetrotide®, Clomid, Clomiphene, Follistim AQ®, Ganirelix®, Gonal-F®, Human Chorionic Gonadotropin, Leuprolide
    Drug Therapy Guidelines Fertility Medications: Bravelle®, Cetrotide®, Clomid, clomiphene, Follistim AQ®, Ganirelix®, Gonal-F®, human chorionic gonadotropin, leuprolide, Menopur®, Novarel®, Ovidrel®, Pregnyl®, Crinone®, Applicable* Endometrin®, First-Progesterone®, progesterone in oil Medical Benefit x Effective: 08/03/2021 Pharmacy- Formulary 1 x Next Review: 6/22 Pharmacy- Formulary 2 x Date of Origin: 7/00 Pharmacy- Formulary 3/Exclusive x Review Dates: 7/12/00, 5/8/01, 1/15/02, 5/6/03, 12/16/03, 6/8/04, Pharmacy- Formulary 4/AON x 12/16/05, 2/1/06, 10/15/06, 7/20/07, 11/5/07, 12/15/08, 12/09, 9/10, 1/11, 9/11, 9/12, 9/13, 9/14, 6/15, 6/16, 6/17, 6/18, 6/19, 9/19, 3/20, 6/20, 9/20, 3/21, 6/21 I. Medication Description Gonadotropin Releasing Hormone (GnRH) Agonists are indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. GnRH Antagonists are indicated for inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. Gonadotropins, FSH, or combination of FSH/LH are indicated for stimulation of ovarian follicular growth. Human chorionic gonadotropins (hCG) are indicated for inducing ovulation. Clomiphene is a selective-estrogen receptor-modulator (SERM) used for inducing ovulation. Therapeutic Class Agents GnRH Agonists leuprolide GnRH Antagonists Cetrotide®, Ganirelix® Gonadotropins Follitropin alfa: Gonal-F®, Gonal-F RFF® (non-preferred) Follitropin beta: Follistim AQ® (preferred) Menotropins: Menopur® Urofollitropins: Bravelle® hCG human chorionic gonadotropin, Novarel®, Ovidrel®, Pregnyl® Progestin Injection progesterone oil for injection Vaginal Progesterone Crinone, Endometrin, First-Progesterone Selective-estrogen receptor- Clomid*, Clomiphene* modulator (SERM) II.
    [Show full text]
  • Mouse Model of Male Germ Cell Apoptosis in Response to a Lack of Hormonal Stimulation
    Indian Journal of Experimental Biology Vol. 43, November 2005, pp. 1048-1057 Mouse model of male germ cell apoptosis in response to a lack of hormonal stimulation Ami ya P Sinha Hikim*, Yanira Vera, Rashid I Elhag, Yanhe Lue, Yu-Gui Cui , Vanisha Pope, Andrew Leun g, Vince Atienza, Christina Wan g & Ron ald S Swerdloff Di vision of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance. Californi a. USA Received 5 August 2005 As a prerequisite for studies using mutant mi ce, we established a mouse model for induction of male germ ce ll apoptosis after depri vation of gonadotropins and intratesti c ul ar testosterone (T). We employed a potent long acting gonadotropin-releasing hormone antagoni st (GnRH-A), acyline, al one or in combinati on with an anti and rogen, flutamide for effective inducti on of germ cell apoptosis in mice. Combined treatment with continuous release of acyline (3 mg/kg BW/day) with flutamide (in the form of sc pellets of 25 mg) resul ted in almost th e same level of suppression of spermatogenesis, as judged by testi s weight and by germ cell apoptotic index, in 2 weeks as th at re ported for rats after treatment with 1.25 mg/kg BW Nai-Giu GnRH-A for the same time peri od. Within the study paradi gm, the maximum suppression of spermatogenesis occurred after a single sc injecti on of hi gh (20 mg/kg BW) dose of acyli ne with flutamide.
    [Show full text]
  • The Effect of Gonadotropin Withdrawal and Stimulation with Human Chorionic Gonadotropin on Intratesticular Androstenedione and DHEA in Normal Men
    ORIGINAL ARTICLE Endocrine Research The Effect of Gonadotropin Withdrawal and Stimulation with Human Chorionic Gonadotropin on Intratesticular Androstenedione and DHEA in Normal Men M. Y. Roth, S. T. Page, K. Lin, B. D. Anawalt, A. M. Matsumoto, B. Marck, W. J. Bremner, and J. K. Amory Downloaded from https://academic.oup.com/jcem/article/96/4/1175/2720870 by guest on 02 October 2021 Departments of Internal Medicine (M.Y.R., S.T.P., B.D.A., A.M.M., W.J.B., J.K.A.) and Obstetrics and Gynecology (K.L.) and Center for Research in Reproduction and Contraception (M.Y.R., S.T.P., B.D.A., A.M.M., W.J.B., J.K.A.), University of Washington, Seattle, Washington 91895; and Geriatric Research (B.M.), Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98105 Introduction: Concentrations of intratesticular (IT) testosterone (T) are known to be 100–200 times those of serum T; however, the IT concentrations of T’s precursors, their testicular to serum gra- dients, gonadotropin dependence, and response to stimulation with human chorionic gonado- tropin (hCG) have not been studied in detail. We hypothesized that serum and IT androstenedione (ADD) and IT dehydroepiandrosterone (DHEA) would be significantly suppressed by the adminis- tration of a GnRH antagonist and increased when stimulated by hCG, without a similar suppression of serum DHEA. Methods: We suppressed gonadotropins in 23 normal men with the GnRH antagonist acyline and randomly assigned them to one of four doses of hCG, 0, 15, 60, or 125 IU sc every other day for 10 d.
    [Show full text]